Research and Markets: US Automated Microbiology Market 2015-2019 - Competitive Strategies, Supplier Shares, Country Segment Forecasts, Innovative Technologies & Instrumentation Review

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/8lnzsc/20152019_us) has announced the addition of the "2015-2019 US Automated Microbiology Market--Competitive Strategies, Supplier Shares, Country Segment Forecasts, Innovative Technologies, Instrumentation Review" report to their offering.

2015-2019 US Automated Microbiology Market is a new analysis of major business opportunities emerging in the US automated microbiology market during the next five years. The report examines key trends, reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding US microbiology market, in evaluating emerging opportunities and developing effective business strategies.

The companies analyzed in the report include:

  • Abbott
  • Affymetrix
  • Agilent Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biokit
  • bioMerieux
  • Bio-Rad
  • Biotest
  • Cepheid
  • CellMark Forensics/LabCorp
  • Decode Genetics
  • Diadexus
  • Diamedix/Erba
  • DiaSorin
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Exact Sciences
  • Fujirebio
  • Girfols
  • Hologic/Gen-Probe
  • Illumina
  • ID Biomedical/GSK
  • Kreatech/Leica
  • Li-Cor Biosciences
  • Lonza
  • Monogram Biosciences
  • Myriad Genetics
  • Ortho-Clinical Diagnostics
  • Perkin Elmer/Caliper
  • Proteome Sciences
  • Qiagen
  • Roche

For more information visit http://www.researchandmarkets.com/research/8lnzsc/20152019_us

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics